Cargando…
Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
Venous thromboembolic disease (VTED) is a common and clinically important complication in patients with cancer, contributing to its mortality and morbidity. Direct oral anticoagulant agents (DOACs), including direct thrombin inhibitors and direct factor Xa inhibitors, are as effective as vitamin K a...
Autores principales: | García-Escobar, I., Brozos-Vázquez, E., Gutierrez Abad, D., Martínez-Marín, V., Pachón, V., Muñoz Martín, A. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084841/ https://www.ncbi.nlm.nih.gov/pubmed/33206333 http://dx.doi.org/10.1007/s12094-020-02506-4 |
Ejemplares similares
-
Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016) -
Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants
por: Kim, Sang-A, et al.
Publicado: (2019) -
Direct Oral Anticoagulants and Travel-related Venous Thromboembolism
por: Chamnanchanunt, Supat, et al.
Publicado: (2018) -
Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
por: Nakamura, Mashio, et al.
Publicado: (2017) -
Direct oral anticoagulants for unusual‐site venous thromboembolism
por: Riva, Nicoletta, et al.
Publicado: (2021)